Amgen slips on eczema drug results

Amgen stock dipped early after producing results from two recent drug studies.
A drug that treats atopic dermatitis appeared less useful compared with Sanofi's current drug.
Dow Jones sinks despite US housing stats showing better than expected New Home Sales.
Positive results also followed Phase 3 trial of Uplizna.

Clay Webster FXStreet

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results of several drug trials.

The Dow Jones Industrial Average (DJIA), of which Amgen is a member, fell 0.4% against a backdrop of an improving NASDAQ. The DJIA has been wobbly all week.

US housing data early in the session showed that mortgage applications were rising. Additionally, New Home Sales in the US fell 4.7% MoM but were not as bad as expected.

Amgen stock news

Amgen released results from two studies late Tuesday after the market close, both of which proved positive.

First, its Phase 3 trial for Uplizna, a drug that treats IgG4-type diseases, showed an 87% reduction in IgG4-RD flare-ups. It also met all three secondary endpoints. Uplizna has been approved for treating neuromyelitis optica spectrum disorder.

Second, its Phase 3 study of rocatinlimab, which treats atopic dermatitis, was statistically significant. Following 24 weeks of treatment, nearly 33% of patients saw at least a 75% improvement in the severity of eczema.

However, this last study was the negative issue for investors. The Sanofi-created and Regeneron-marketed Dupixent drug, which is focused on the same use case, achieved figures of 51% and 44% during its two Phase 3 studies compared with Amgen’s 33%. Hence, Amgen’s drug works but not quite as well as that of its competitors.

In reporting by industry website Fierce Biotech, Amgen Executive Vice President Murdo Gordon was not dissuaded. Gordon said that more than one drug was needed to meet the needs of patients in the atopic dermatitis market and that Amgen’s data suggested that doctors often switch prescriptions early on in treatment. Rocatinlimab’s use of a different mechanism for treatment might also persuade some physicians, according to Gordon.

Amgen stock forecast

Amgen stock is up 9.5% year to date and 24% over the past year despite dropping to $315 on Wednesday. Seeing as the pharma stock slid easily below the 100-day Simple Moving Average (SMA) on Wednesday, it could be foolish to think that the 200-day SMA might hold, which is now near $302.

If it fails to hold, then traders will look to $296, which held up earlier this summer. Below there is resistance turned support at $260, which was treated with respect throughout 2023. However, a break back above $320 would put an end to bearish sentiment.

AMGN daily stock chart

Author

Clay Webster

FXStreet

Clay Webster grew up in the US outside Buffalo, New York and Lancaster, Pennsylvania. He began investing after college following the 2008 financial crisis.

USD/JPY eyes August swing low, near 155.20 ahead of US NFP

USD/JPY retests the August monthly swing low during the Asian session on Friday as a more hawkish repricing of BoJ rate-hike bets and a suspected intervention continue to underpin the Japanese Yen. Meanwhile, the US Dollar is seen consolidating the previous day's heavy losses amid soft US bond yields, further weighing on the currency pair as traders keenly await the US NFP report.

AUD/USD consolidates above 0.7200; US NFP awaited

AUD/USD holds steady above 0.7200, near its highest level since mid-May, as bulls await the US NFP report for more cues on the Fed's policy path before placing fresh bets. Meanwhile, the recent decline in US bond yields keeps the US Dollar depressed near its lowest level in over a week and acts as a tailwind for the Aussie amid the RBA's hawkish tilt.

Gold holds steady below $4,500; looks to US NFP for fresh impetus

Gold consolidates its strong gains recorded over the past two days and trades below $4,500 during the Asian session on Friday, awaiting the US NFP report for cues about the Fed's policy path amid reduced September rate-hike bets. In the meantime, the recent fall in US bond yields keeps the US Dollar depressed and acts as a tailwind for the non-yielding bullion.

Bitcoin and Gold Outlook: BTC and XAU recover as US ISM Services PMI edges higher in August

Bitcoin (BTC) strongly rises to trade above the pivotal $80,000 level on Thursday. The Crypto King is rallying alongside broader cryptocurrency prices following the release of the United States (US) Services PMI. Gold (XAU/USD) is similarly bullish, trading at $4,500 at the time of writing. The metal is up over 2% on the day, signaling the return of bulls as market sentiment improves.

Canada's 6.4% unemployment rate: Why Friday's jobs print puts the BoC's slack story on trial

The Bank of Canada (BoC) held at 2.25% on Wednesday for a seventh straight meeting and rewrote the one paragraph that still argues against a hike. In July, the BoC’s statement called the labour market soft and pinned the unemployment rate inside a 6.5%-7% range it had held since the end of 2024. July's Labour Force Survey (LFS) then printed 6.4%.

Diesel’s record $100 warning: The oil shock hiding in plain sight

The Oil market may look calmer than it did a few months ago, but diesel is sending a very different message. The US diesel crack spread, the premium of ultra-low sulphur diesel futures over WTI, recently surged above $100 per barrel for the first time, reaching an intraday record of just over $102.00.